| | Characteristic | All patients () | Without CV conditions (, 85.5%) | With CV conditions (, 14.5%) | value |
| | Sex | | | | | | Male, (%) | 132 (39.8) | 110 (38.7) | 22 (45.8) | 0.285 | | Female, (%) | 200 (60.2) | 174 (61.3) | 26 (54.2) | 0.285 | | Age, median (IQR) | 51 (40-59) | 50 (39-59) | 56 (45-62) | 0.007 |
| | Symptoms | | | | | | Fever, (%) | 177 (63.2) | 150 (63.3) | 27 (58.7) | 0.487 | | Cough, (%) | 108 (38.4) | 88 (37.6) | 20 (42.6) | 0.525 | | Fatigue, (%) | 39 (13.9) | 26 (11.1) | 13 (28.3) | 0.002 | | Chest tightness, (%) | 32 (11.5) | 14 (6.0) | 18 (40) | <0.001 | | Diarrhea, (%) | 11 (3.9) | 9 (3.8) | 2 (4.3) | 0.873 | | Headache, (%) | 7 (2.5) | 5 (2.1) | 2 (4.3) | 0.323 | | Sore throat, (%) | 4 (1.4) | 4 (1.7) | 0 (0.0) | 1.000 | | Rhinorrhea, (%) | 4 (1.4) | 4 (1.7) | 0 (0.0) | 1.000 | | Myalgia, (%) | 12 (4.3) | 6 (2.6) | 6 (13.0) | 0.001 | | Toothache, (%) | 2 (0.6) | 1 (0.4) | 1 (2.1) | 0.269 |
| | Comorbidities | | | | | | Diabetes, (%) | 11 (3.3) | 7 (2.5) | 4 (8.3) | 0.036 | | Lung disease, (%) | 7 (2.1) | 3 (1.1) | 4 (8.3) | 0.010 | | Radiologic abnormality,(%) | 201 (65.5) | 182 (67.2) | 19 (52.8) | 0.088 |
| | Positive SARS-CoV-2 testing by RT-PCR | | | | | | Twice or more, (%) | 72 (23.0) | 60 (22.0) | 12 (35.1) | 0.147 | | Once, (%) | 241 (77.0) | 216 (78.0) | 25 (64.9) | 0.147 |
| | Laboratory findings | | | | | | Red blood cell count (1012/L), median (IQR) | 4.39 (4.05-4.73) | 4.37 (4.04-4.68) | 4.49 (4.15-4.90) | 0.159 | | White cell count (109/L), median (IQR) | 5.25 (4.49-6.37) | 5.25 (4.49-6.37) | 5.00 (4.46-6.35) | 0.677 | | Neutrophil count (109/L), median (IQR) | 3.21 (2.57-4.08) | 3.23 (2.59-4.10) | 3.06 (2.53-3.91) | 0.468 | | Lymphocyte count (109/L), median (IQR) | 1.61 (1.26-1.91) | 1.58 (1.27-1.91) | 1.72 (1.23-1.92) | 0.745 | | NLR, median (IQR) | 2.06 (1.60-2.67) | 2.07 (1.60-2.67) | 2.04 (1.56-2.54) | 0.609 | | Platelet count (109/L), median (IQR) | 258 (216-310) | 263 (217-314) | 243 (202-287) | 0.085 | | Hemoglobin (g/L), median (IQR) | 135 (125-145) | 135 (125-145) | 137 (130-145) | 0.254 |
| | C-reactive protein | | | | | | <10.00 mg/L | 261 (85.0) | 230 (85.8) | 31 (79.5) | 0.300 | | ≥10.00 mg/L | 46 (15.0) | 38 (14.2) | 8 (20.5) | 0.300 | | Median length of symptom onset to admission (days) (IQR) | 12 (8-16) | 12 (8-15) | 14 (8-18) | 0.222 | | Median length of temporary hospital stay (days) (IQR) | 14 (10-19) | 14 (10-19) | 15 (8-20) | 0.837 |
| | Clinical outcomes | | | | | | Discharge, (%) | 274 (82.5) | 249 (87.6) | 25 (52.1) | <0.001 | | Require intensive care, (%) | 58 (17.5) | 35 (12.4) | 23 (47.9) | <0.001 |
|
|
